Can open-source drug RD repower pharmaceutical innovation?

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 5, 2010, Pages 534-536

  Munos, B ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

CULTURAL FACTOR; DRUG INDUSTRY; ECONOMICS; KNOWLEDGE; MARKET; MEDICAL RESEARCH; MODEL; NOTE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE;

ANIMALS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; PATENTS AS TOPIC; THERAPIES, INVESTIGATIONAL;

EID: 77951427922     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.26     Document Type: Note

References (9)

1. Barnes, M.R. et al. Lowering industry firewalls. Nat. Rev. Drug Discov. 8, 701-708 (2009).
2. Louise-May, S., Bunin, B. & Ekins, S. Towards integrated Web-based tools in drug discovery. Touch Briefings Drug Discov. 6, 17-21 (2009).
3. Weigelt, J. The case for open-access chemical biology. EMBO Rep. 10, 941-945 (2009).
4. Whitehead, A.N. Science and the Modern World (Macmillan, New York, 1925)
5. Abraham, E. Ernst Boris Chain. Biogr. Mems Fell. R. Soc. 29, 43-91 (1983).
6. Reichardt, J.K. Quo vadis, genoma? A call to pipettes for biochemists. Trends Biochem. Sci. 32, 529-530 (2007).
7. Brandenburger, A. & Harborne, S. Value based business strategy, J Econ. Manage. Strategy 5, 5-24 (1996)
8. De Vany, A. Hollywood Economics (Routledge, London, 2004).
9. Hollingsworth, J.R. A path-dependent perspective on institutional and organizational factors shaping major scientific discoveries. In Innovation, Science, and Institutional Change (eds. Hage, J. & Meeus, M.T.H.) 423-442 (Oxford University Press, Oxford, UK, 2006).